EV71 vaccine study for Vietnamese children
Part of Infections clinical trials.
This study tests an experimental vaccine against hand, foot, and mouth disease in healthy children aged 6 to 71 months. The vaccine aims to protect against the EV71 virus, a common cause of this illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 71 months old when receiving the first dose.
- Your child must be generally healthy, with no serious medical conditions.
- Your child must not have had hand, foot, and mouth disease before.
- Your child must not have been exposed to someone with confirmed hand, foot, and mouth disease in the past 2 weeks.
- Your child must not have received other vaccines within 14 days before the study vaccine.
- Your child must not have a fever (temperature 37.5°C or higher) on the day of vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-in-one vaccine to protect children against hand, foot, and mouth disease caused by two common viruses (EV71 and CA16). It is for healthy kids ages 6 months to 5 years and will check if the vaccine is safe and works well.
This study checks how long immunity lasts after receiving two doses of the EV71 vaccine. It is for children who took part in the earlier study and got either the vaccine or a placebo.
This trial tests a new vaccine that protects against two common causes of hand, foot, and mouth disease, a viral illness that mostly affects young children. It may help prevent this uncomfortable and sometimes serious infection.
This study tests a vaccine to protect against hand, foot, and mouth disease (HFMD) caused by four common viruses. It is for healthy children aged 6 to 71 months, and aims to see if the vaccine is safe and effective.
This study tracks how respiratory syncytial virus (RSV)—a common respiratory infection in babies—affects children under 24 months in Ho Chi Minh City. Researchers want to understand how often RSV happens, how severe it is, and how it impacts families, so they can better prepare healthcare services.
This trial tests two doses of a dengue vaccine in healthy infants and toddlers aged 6 to 21 months. It aims to see if the vaccine is safe and helps protect against dengue fever.
Hear when a new Hand, Foot, and Mouth Disease (HFMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.